Lu DaoPei Medical Group Pre-IPO - Ramp up in Progress but Looks Promising
Lu Daopei Medical Group (1816743D CH) is looking to raise around US$400m in its upcoming Hong Kong IPO. LDPM has supported its growth through its...
391 Views
Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook
Continuous M&A fails to bring ideal performance to Haohai. Medical aesthetics is the main growth driver, but Haohai is lack of competitiveness....
408 Views
Huadong Medicine (000963.CH) 2022H1 - Huadong Is Back on Track. If Shares Pullback, Then Be Long
Huadong released encouraging H1 results.It's back on track. This positive momentum will continue in H2, especially medical cosmetology and...
322 Views
China Healthcare Weekly (Aug.12)-AI Drug Discovery, License-In Mode Valuation, Pet Medical Equipment
AI drug discovery is far from meeting the current investment level and expectations. The success of license-in mode must be based on appropriate...
376 Views
Sihuan Pharmaceutical (460.HK) - The Potential Disposal of Generic Drug Business and the Outlook
The medical aesthetics/innovative drug business face various challenges.Though Sihuan is undervalued,concerns on outlook/development mode will...
312 Views